摘要
目的比较单纯放疗(RT)与放疗加替莫唑胺(RT-TMZ)治疗胶质母细胞瘤的局控率、生存率及不良反应。方法对60例首次术后的胶质母细胞瘤随机分为接受单纯放疗、放疗加每天持续的替莫唑胺治疗以及6个周期的替莫唑胺辅助治疗。每组30例。主要研究目标为整体生存率。结果RT-TMZ组与RT组总有效率分别为53.3%和26.6%;1年累计局部复发率分别为63.3%和90.0%,1年无复发生存率分别为36.7%和10.0%,1年生存率分别为56.7%和16.7%(P〈0.05)。RT-TMZ组常见不良反应是恶心,呕吐,白细胞和血小板下降,但仅限于Ⅰ~Ⅱ度。结论在提高局控率、延缓肿瘤复发与提高患者无瘤生存期方面RT-TMZ组要优于RT组,而不良反应方面两组反应均较轻微。
Objective To compare the rate of local control, survival and safety in patients receiving radiotherapy alone (RT) and radiotherapy plus concomitant and adjuvant tcmozolomide (RT-TMZ) in postoperative patients with glioblastoma. Method 60 postoperative patients with glioblastoma were randomly divided into two groups: RT Group and RT-TMZ Group, each group have 30 patients. The primary end point was overall survial. Results The overall response rate in RT-TMZ Group and RT Group were 53.3% and 26. 6% respectively. The one-year cumulative local failure rate was 63. 3% and 90. 0% respectively. The one-year free from local failure survival rate was 36.7% and 10.0% respectively, The one-year survival rate was 56. 7% and 16.7% respectively ( P 〈 0.05 ). The main side-effect including nausea, vomiting, leucopema, and thrombocytopenia were not serious (grade Ⅰ-Ⅱ ). Conclusions The RT-TMZ Group was well in local control rate, delaying relapse and increasing relapse free survival rate compared with RT Group. The side-effect were little in both groups.
出处
《中华神经外科杂志》
CSCD
北大核心
2008年第7期487-489,共3页
Chinese Journal of Neurosurgery
基金
2005年度首都医学发展科研基金重点支持项目(2005-2-240)